Fu S#, Dai Y#, Zhang P, Zheng K, Cao G, Xu L, Zhong Y, Niu C, Wang X*Extrachromosomal circular DNA (eccDNA) characteristics in the bile and plasma of advanced perihilar cholangiocarcinoma patients and the construction of an eccDNA-related gene prognosis model.,Frontiers in Cell and Developmental Biology,

Fu S, Li J, Fan H, Zheng K, Leng B, Cao G, Xu L, Zhong Y, Niu C, Wang X. NLCECA score: a serum inflammatory-tumor biomarker score to predict survival of advanced perihilar cholangiocarcinoma after hepatic arterial infusion chemotherapy,Sci Rep,Sci Rep. 2024 Feb 23;14(1):4466. doi: 10.1038/s41598-024-53883-7.

Zheng K, Wang X. Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers,Ther Adv Med Oncol,Ther Adv Med Oncol. 2024 Jan 27;16:17588359231225040. doi: 10.1177/17588359231225040. eCollection 2024.

Zheng K, Zhu X, Fu S, Cao G, Li WQ, Xu L, Chen H, Wu D, Yang R, Wang K, Wang X*. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.,Radiology,2022:211545.

Zheng K, Fu S, Leng B, Cui Y, Yang R, Cao G, Xu L, Li W-Q, Li Y, Zhu X，Wang X*. Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers.,Insights into Imaging,2022, 14;13(1):46.

Zheng K, Wang X*, Cao G, Xu L, Zhu X, Fu L, Fu S, Cheng H, Yang R: Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Gallbladder Cancer.,Cardiovascular and interventional radiology,2021 Feb;44(2):271-280.

Jungang Hu, Guang Cao, Liang Xu, Kanglian Zheng, Xu Zhu, Renjie Yang, Xiao Wang, Xiaodong Wang*. Retrograde embolization technique of the right gastric artery during the implantation of port-catheter system for hepatic arterial infusion chemotherapy.,Journal of Interventional Medicine,

郑康炼，王晓东* 胆道恶性肿瘤系统治疗与局部治疗的现状及进展,临床肝胆病杂志,2022.2:483-488

基于多模态影像组学和液态活检多组学的肝门胆管癌人工智能辅助HAIC 疗效预测和评效模型研究, 课题负责人, 2022.1.1～2025.12.31, 国家自然科学基金面上项目

重点培育专业：肝胆肿瘤微创介入学, 课题负责人, 2021.1.1～2023.12.30, 临床医学发展专项“扬帆”计划重点医学专业（重点培育专业）

“基于免疫微环境的冷冻消融对PD1免疫检查点抑制剂治疗肝癌的协同机制研究”, 课题负责人, 2021.1.1～2023.12.30, 北京市自然科学基金面上项目